Description

DESCRIPTION

Semaglutide is a long‑acting GLP‑1 receptor agonist engineered with specific amino‑acid substitutions and a C18 fatty‑acid chain to enhance metabolic stability and extend circulating half‑life. Research explores its influence on glucose homeostasis, pancreatic β‑cell responses, gut–brain appetite signaling, energy‑balance pathways, cardiometabolic markers, and endocrine‑regulated mechanisms. All findings referenced are strictly for laboratory and mechanistic research models.

LYOPHILIZED PEPTIDES

This peptide is supplied in freeze‑dried (lyophilized) form to maintain purity, structural integrity, and storage stability. No fillers or excipients are used.

RESEARCH APPLICATIONS

1 — Glucose Regulation & GLP‑1 Receptor Pathways

Semaglutide is widely used in research to evaluate GLP‑1–mediated insulin secretion, glucagon suppression, hepatic glucose output, and metabolic signaling circuitry. Its long‑acting structure allows modeling of sustained incretin‑pathway effects.

(References: Nature—https://www.nature.com/articles/s41591-023-02590-2, PubMed—https://pubmed.ncbi.nlm.nih.gov/37365087/ )

2 — Appetite, Satiety & Weight‑Regulation Mechanisms

Laboratory models apply semaglutide to investigate gut‑brain axis signaling, appetite modulation, satiety responses, energy intake, and weight‑regulation pathways involving GLP‑1–dependent receptor circuits.

(References: ScienceDirect—https://www.sciencedirect.com/science/article/pii/S1550413123002073, PubMed—https://pubmed.ncbi.nlm.nih.gov/37581871/ )

3 — Cardiometabolic & Inflammatory Pathway Research

Studies examine semaglutide’s effects on inflammation markers, endothelial signaling, oxidative‑stress responses, lipid metabolism, and long‑term cardiometabolic modeling. Its incretin‑based mechanism provides broad relevance for systemic metabolic research.

(References: MDPI—https://www.mdpi.com/1422-0067/24/3/2341, PubMed—https://pubmed.ncbi.nlm.nih.gov/36638174/ )

4 — Comparative Incretin & Multi‑Agonist Modeling

Semaglutide is commonly used as a reference tool in research evaluating dual agonists, triple agonists, and variant GLP‑1 analogues for receptor‑selectivity, half‑life modifications, and metabolic outcomes.

(References: Frontiers—https://www.frontiersin.org/articles/10.3389/fendo.2023.1211441/full, PubMed—https://pubmed.ncbi.nlm.nih.gov/36971244/ )

SPECIFICATIONS

Property | Details

Peptide Name | Semaglutide

Type | GLP‑1 Receptor Agonist

Amino Acid Length | 31‑amino‑acid modified GLP‑1 analogue

CAS Number | 910463‑68‑2

Molecular Formula | C187H291N45O59

Molecular Weight | ~4113.6 Da

Purity | ≥ 99% (HPLC verified)

Appearance | White to off‑white lyophilized powder

Solubility | Soluble in sterile/bacteriostatic water

Storage | Store dry at −20 °C; Refrigerate after reconstitution; protect from light

Usage | Laboratory research only

Research Data & References

– GLP‑1 metabolic pathway studies: https://pubmed.ncbi.nlm.nih.gov/37365087/

– Glycemic stability & endocrine signaling: https://pubmed.ncbi.nlm.nih.gov/37581871/

– Hepatic/lipid metabolic models: https://pubmed.ncbi.nlm.nih.gov/36638174/

Research Disclaimer

RESEARCH USE ONLY.
This product is not intended for therapeutic or diagnostic use. EOC Labs products are sold strictly for laboratory research and analytical purposes only. All information provided by EOC Labs, including descriptions, references, and technical data, is intended solely for educational and informational purposes. Statements have not been evaluated by the U.S. Food and Drug Administration (FDA). No claims are made for any medical or consumer application. By purchasing this product, the buyer certifies that it will be handled by qualified professionals in a properly equipped laboratory and used in compliance with all applicable local, state, and federal laws and regulations.